Edward Shelton

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

Edward Shelton, Jessica R. Allegretti, Betsy W. Stevens et al. · Inflammatory Bowel Diseases · 2015 · 180 citations · Full text

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 62 citations · Full text

Placebo-controlled Induction, Gastroenterology, Pathology +6

New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease

Edward Shelton, Khadija Chaudrey, Jenny Sauk et al. · Alimentary Pharmacology & Therapeutics · 2015 · 61 citations · Full text

Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial

Julien D. Schulberg, Emily K. Wright, Bronte A. Holt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 59 citations

Gastrointestinal Pharmacology, Gastroenterology, Therapeutic Controversy +6

Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn’s Disease and Need for Parenteral Support Due to Short Bowel Syndrome–associated Intestinal Failure

Bharati Kochar, Millie D. Long, Edward Shelton et al. · Journal of Clinical Gastroenterology · 2016 · 57 citations · Full text

Functional Gastrointestinal Disorder, Ivf Requirements, Short Bowel Syndrome +12